Compare HIMX & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | BCRX |
|---|---|---|
| Founded | 2001 | 1986 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2006 | 1995 |
| Metric | HIMX | BCRX |
|---|---|---|
| Price | $7.38 | $8.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.82 |
| AVG Volume (30 Days) | 1.1M | ★ 4.0M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 4.82% | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | N/A | ★ 1.21 |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $7.79 | $12.55 |
| P/E Ratio | $14.99 | ★ $7.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.66 | $6.00 |
| 52 Week High | $9.85 | $11.31 |
| Indicator | HIMX | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 69.72 |
| Support Level | $7.14 | $7.95 |
| Resistance Level | $8.85 | $8.68 |
| Average True Range (ATR) | 0.29 | 0.33 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 45.51 | 81.19 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.